Literature DB >> 3945574

Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children.

M Leinonen, A Säkkinen, R Kalliokoski, J Luotonen, M Timonen, P H Mäkelä.   

Abstract

Antibody responses to 14-valent pneumococcal capsular polysaccharide vaccine were measured by Farr-type radioimmunoassay in children younger than 7 years of age. On the basis of immunogenicity in young children individual pneumococcal polysaccharides could be identified as uniformly good, strongly age-dependent or uniformly poor immunogens. Pneumococcal types 6A and 23F, which frequently cause pneumococcal infections in small children, were the poorest immunogens in this age group. The children younger than 2 years of age responded very poorly also to types 19F and 18C whereas older children had good antibody responses to these types. The results support the current view that present pneumococcal polysaccharide vaccines are not beneficial in children younger than 2 years of age and stress the importance of attempts to improve their immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3945574     DOI: 10.1097/00006454-198601000-00008

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  27 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

2.  Pneumonia in childhood: etiology and response to antimicrobial therapy.

Authors:  O Ruuskanen; H Nohynek; T Ziegler; R Capeding; H Rikalainen; P Huovinen; M Leinonen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

3.  Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

Authors:  W T Jansen; S Hogenboom; M J Thijssen; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

5.  Serotype-specific anti-pneumococcal IgG and immune competence: critical differences in interpretation criteria when different methods are used.

Authors:  Anne Balloch; Paul V Licciardi; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2012-09-30       Impact factor: 8.317

6.  Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines.

Authors:  J Kuo; M Douglas; H K Ree; A A Lindberg
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

Review 7.  Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection.

Authors:  Malcolm J M Darkes; Greg L Plosker
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

8.  Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation.

Authors:  M A Avanzini; A M Carra; R Maccario; M Zecca; P Pignatti; M Marconi; P Comoli; F Bonetti; P De Stefano; F Locatelli
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

9.  Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea.

Authors:  W S Pomat; D Lehmann; R C Sanders; D J Lewis; J Wilson; S Rogers; T Dyke; M P Alpers
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Severity of infections in IgA deficiency: correlation with decreased serum antibodies to pneumococcal polysaccharides and decreased serum IgG2 and/or IgG4.

Authors:  M A French; K A Denis; R Dawkins; J B Peter
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.